Matikainen N - Search Results

1

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.

Matikainen N, Björnson E, Söderlund S, Borén C, Eliasson B, Pietiläinen KH, Bogl LH, Hakkarainen A, Lundbom N, Rivellese A, Riccardi G, Després JP, Alméras N, Holst JJ, Deacon CF, Borén J, Taskinen MR. Matikainen N, et al. PLoS One. 2016 Jan 11;11(1):e0145890. doi: 10.1371/journal.pone.0145890. eCollection 2016. PLoS One. 2016. PMID: 26752550 Free PMC article. Clinical Trial.

2

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR. Matikainen N, et al. Diabetologia. 2006 Sep;49(9):2049-57. doi: 10.1007/s00125-006-0340-2. Epub 2006 Jul 1. Diabetologia. 2006. PMID: 16816950 Clinical Trial.

3

The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity.

Kahri J, Fruchart-Najib J, Matikainen N, Fruchart JC, Vakkilainen J, Taskinen MR. Kahri J, et al. Among authors: matikainen n. Diabetes Care. 2007 Aug;30(8):2083-5. doi: 10.2337/dc07-0100. Epub 2007 May 7. Diabetes Care. 2007. PMID: 17485571 No abstract available.

4

Postprandial lipemia associates with liver fat content.

Matikainen N, Mänttäri S, Westerbacka J, Vehkavaara S, Lundbom N, Yki-Järvinen H, Taskinen MR. Matikainen N, et al. J Clin Endocrinol Metab. 2007 Aug;92(8):3052-9. doi: 10.1210/jc.2007-0187. Epub 2007 May 8. J Clin Endocrinol Metab. 2007. PMID: 17488790

5

Reviewing statin therapy in diabetes--towards the best practise.

Matikainen N, Kahri J, Taskinen MR. Matikainen N, et al. Prim Care Diabetes. 2010 Apr;4(1):9-15. doi: 10.1016/j.pcd.2010.01.005. Epub 2010 Feb 19. Prim Care Diabetes. 2010. PMID: 20171948

6

Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in type 2 diabetes and the metabolic syndrome.

Tushuizen ME, Pouwels PJ, Bontemps S, Rustemeijer C, Matikainen N, Heine RJ, Taskinen MR, Diamant M. Tushuizen ME, et al. Among authors: matikainen n. Atherosclerosis. 2010 Jul;211(1):308-14. doi: 10.1016/j.atherosclerosis.2010.02.002. Epub 2010 Feb 10. Atherosclerosis. 2010. PMID: 20227695

7

PPARalpha: an emerging therapeutic target in diabetic microvascular damage.

Hiukka A, Maranghi M, Matikainen N, Taskinen MR. Hiukka A, et al. Among authors: matikainen n. Nat Rev Endocrinol. 2010 Aug;6(8):454-63. doi: 10.1038/nrendo.2010.89. Epub 2010 Jun 22. Nat Rev Endocrinol. 2010. PMID: 20567246 Review.

8

Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat.

Matikainen N, Taskinen MR, Stennabb S, Lundbom N, Hakkarainen A, Vaaralahti K, Raivio T. Matikainen N, et al. Eur J Endocrinol. 2012 Mar;166(3):487-92. doi: 10.1530/EJE-11-0783. Epub 2011 Dec 21. Eur J Endocrinol. 2012. PMID: 22190000

9

Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity.

Adiels M, Matikainen N, Westerbacka J, Söderlund S, Larsson T, Olofsson SO, Borén J, Taskinen MR. Adiels M, et al. Among authors: matikainen n. Atherosclerosis. 2012 May;222(1):222-8. doi: 10.1016/j.atherosclerosis.2012.02.001. Epub 2012 Feb 7. Atherosclerosis. 2012. PMID: 22365426

10

Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.

Matikainen N, Taskinen MR. Matikainen N, et al. Curr Cardiol Rep. 2012 Dec;14(6):721-31. doi: 10.1007/s11886-012-0309-3. Curr Cardiol Rep. 2012. PMID: 22941588 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page